Let’s Go Down the Correct Path(way)

To the Editor:
“Acquired Liver Injury in the Intensive Care Unit” by Lescot et al.1 is an excellent discussion of the multifaceted causes of liver injury. One correction is in order, however. The review incorrectly states that the international normalized ratio reflects intrinsic pathway activity. It is the activity of the extrinsic coagulation pathway, often now referred to as the tissue factor pathway, that is measured by the international normalized ratio and initiates the coagulation cascade.² An understanding of the specific pathway measured by a coagulation test is paramount to the treatment of defects secondary to liver disease. It should also be pointed out that the international normalized ratio, one component of the model for end-stage liver disease scoring used to prioritize liver transplantation waiting lists, can be highly variable depending on the laboratory analyzing the sample.³

Matthew R. Johnson, M.D., Mark J. Rice, M.D.*University of Florida College of Medicine, Gainesville, Florida. mrice@anest.ufl.edu

References
3. Trotter JF, Brimhall B, Ariëls R, Phillips C: Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation. Liver Transpl 2004; 10:995–1000

In Reply:
We thank Drs. Johnson and Rice for correcting our inadvertent error from our article¹ and agree with their comments.

Thomas Lescot, M.D., Ph.D.,* Constantine Karvellas, M.D., F.R.C.P.C., Marc Beaussier, M.D., Ph.D., Sheldon Magder, M.D., F.R.C.P.C. *Royal Victoria Hospital, McGill University Health Center, Montreal, Quebec, Canada. thomas.lescot@sat.aphp.fr

Reference

Intralipid: The New Magic Bullet in Cardioprotection?

To the Editor:
In two recent publications in Anesthesiology, Dr. Eghbali’s group reports the attenuation of myocardial reperfusion injury in rodents by intralipid administered on reperfusion.¹,² Taken together with another study by the same group in which intralipid prevents and even rescues pulmonary hypertension,³ and the serendipitous landmark discoveries of lipid rescue therapy against bupivacaine-induced cardiotoxicity first in dogs⁴ and then humans,⁵ intralipid appears to have become a new magic bullet for cardioprotection. Nevertheless, many questions remain. Li et al.⁶ state that intralipid acts through the phosphorylation of Akt/extracellular signal-regulated kinase (AKT/ERK) and glycogen

Research funding provided in part by the Department of Veterans Affairs, Washington, D.C. (CRA-026-10F to M.L.R.), the National Institutes of Health, Bethesda, Maryland (5R01 HL098490-03 to M.L.R. and NIH R01 HL092071 to M.V.P.), and institutional funds.
Matthias L. Riess, M.D., Ph.D.,* Mihai V. Podgoreanu, M.D. *Veterans Affairs Medical Center, and Medical College of Wisconsin, Milwaukee, Wisconsin. mriess@mcw.edu

References


(accepted for publication January 29, 2013.)